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Abstract
Acute myeloid leukemia (AML) is caused by genetic aberrations that also govern the prognosis of patients and guide risk-
adapted and targeted therapy. Genetic aberrations in AML are structurally diverse and currently detected by different
diagnostic assays. This study sought to establish whole transcriptome RNA sequencing as single, comprehensive, and flexible
platform for AML diagnostics. We developed HAMLET (Human AML Expedited Transcriptomics) as bioinformatics
pipeline for simultaneous detection of fusion genes, small variants, tandem duplications, and gene expression with all
information assembled in an annotated, user-friendly output file. Whole transcriptome RNA sequencing was performed on
100 AML cases and HAMLET results were validated by reference assays and targeted resequencing. The data showed that
HAMLET accurately detected all fusion genes and overexpression of EVI1 irrespective of 3q26 aberrations. In addition, small
variants in 13 genes that are often mutated in AML were called with 99.2% sensitivity and 100% specificity, and tandem
duplications in FLT3 and KMT2A were detected by a novel algorithm based on soft-clipped reads with 100% sensitivity and
97.1% specificity. In conclusion, HAMLET has the potential to provide accurate comprehensive diagnostic information
relevant for AML classification, risk assessment and targeted therapy on a single technology platform.
Introduction
Acute myeloid leukemia (AML) is caused by functionally
complementary genetic mutations that cause uncontrolled
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proliferation and maturational arrest of myeloid precursor
cells [1, 2]. Overt AML carry on average 13 nonsynon-
ymous mutations [3, 4]. Acquisition of AML-initiating
mutations in hematopoietic stem cells can precede AML
diagnosis by decades [5–7]. The 2016 revision of the WHO
classification of hematologic malignancies [8] distinguishes
nine AML subtypes of clinical and prognostic importance.
Genetic aberrations permit precise classification with risk
assessment in 50–55% of AML cases and may guide tar-
geted therapy. A proposed genomic classification based on
an extended panel of recurrently mutated genes permits
classification of 80–85% of AML cases [9].
Accurate classification of AML, however, requires dif-
ferent techniques to capture structurally diverse genetic
abnormalities such as larger insertions and deletions
(indels), fusion genes, and structural chromosomal aberra-
tions in addition to small variants. Moreover, expression
levels of structurally normal genes can have decisive
prognostic impact [10–12]. Therefore, AML diagnosis and
risk assessment remains complex, expensive, and frequently
incomplete with current technological platforms. To address
this unmet medical need, we implemented whole tran-
scriptome messenger RNA sequencing (mRNAseq) without
concomitant sequencing of germ-line DNA as a single
platform to acquire all genetic information relevant for
current and future classification and risk categorization. In
this diagnostic paradigm, an accredited mRNAseq protocol
acquires comprehensive data on a diagnostic sample. For
single-run data analysis, we developed an integrated
bioinformatic pipeline designated (Human AML Expedited
Transcriptomics (HAMLET); Fig. 1). HAMLET is flexibly
adaptable and tailored to interrogate sequence variants and
expression levels of a selected panel of genes as well as
translocations from mRNAseq data.
In this report, we apply HAMLET (version 1.0) for AML
classification according to the WHO 2016 [8] and genomic
classifications [9] and for risk assessment according to the
European Leukemia Net [1].
Materials and methods
AML samples
One hundred cryopreserved AML samples obtained with
written informed consent were selected from the Hematol-
ogy Biobank of Leiden University Medical Center (LUMC)
with approval by the institutional review board (no. B
18.047). All samples had been genotyped for NPM1
mutations and FLT3 internal tandem duplications (FLT3-
ITD) by the accredited LUMC molecular diagnostic
laboratory.
Whole messenger transcriptome sequencing
At least 1 µg of total RNA was isolated from mononuclear
cells per sample without prior enrichment for leukemic
blasts (RNAqueous kit, Thermo Fisher Scientific, Bleiswijk,
Fig. 1 The bioinformatics pipeline HAMLET. HAMLET was
developed as a bioinformatics pipeline to call all relevant information
for diagnosis and prognosis of AML from raw mRNAseq data.
HAMLET integrates four modules using algorithms to detect fusion
genes (STARfusion ∩ FusionCatcher), small variants (VARSCAN),
large tandem duplications (ReSCU), and gene expression. HAMLET
permits immediate AML classification into subtypes according to
WHO 2016 or genomic classifications, provides additional prognostic
information according to the European Leukemia Net, and identifies
molecular targets for therapy.
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The Netherlands), followed by treatment with DNAse I and
silica membrane purification (RNeasy kit, Qiagen, Hilden,
Germany). RNA was quantified using the Qubit RNA
HS assay kit (Thermo Fisher Scientific) and diluted to
100 ng/µl. The quality of total RNA was confirmed by
Fragment Analyzer (Advanced Analytical Technologies,
Heidelberg, Germany). Samples with RNA quality numbers
≥6 were selected for RNA library preparation in an ISO/IEC
17025-accredited protocol (TruSeq RNA library preparation
kit v2, Illumina, San Diego, CA). After enrichment of
mRNA by oligo dT magnetic beads and fragmentation,
cDNA synthesis was performed, followed by adapter liga-
tion and PCR amplification. Paired-end sequencing with a
read length of 126 bp was performed on an Illumina HiSeq
2500v4 sequencer to at least 12.5 Gbp per sample according
to the manufacturer’s protocol, yielding ~50 million read
pairs. Image analysis, base calling, and quality check was
performed with Illumina data analysis pipeline RTA
v1.18.64 and Bcl2fastq v1.8.4. RNAseq reads were pro-
vided in compressed Sanger FASTQ format.
Quality parameters and alignment to human
reference genome
Each input sample file was analyzed by FastQC (version
0.10.1). Known overrepresented sequences detected by
FastQC were used for adapter clipping using cutadapt
(version 1.2) setting the minimum accepted read length to
20 bp. Low-quality bases were then trimmed using sickle
(version 1.33). Each read pair was synchronized to maintain
the pair ordering using a custom Python script and were
merged into a single file. Read pairs were aligned to human
reference genome GRCh38 using GSNAP aligner (version
2014-12-23), setting it for novel splice sites discovery
(--novel splicing 1) and unique alignments only (--npaths 1
and --quiet-if-excessive). Output SAM files were com-
pressed, position-sorted, and indexed using Picard suite
(version 1.141).
Fusion genes
Fusion genes were detected with STAR-Fusion (version
0.5.4) and FusionCatcher (version 0.99.5a). The resulting
calls were intersected using FuMa (version 3.0.5) and
plotted using Circos (version 0.69). For AML classification,
detected fusion transcripts were filtered for the presence of
RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, DEK-
NUP214 gene fusions, as well as fusions involving KMT2A.
Gene expression
To measure expression levels of individual exons, the total
number of single read bases aligned to that exon was
calculated. This number was normalized to exon length and
to the total number of aligned bases for each sample.
Similarly, to calculate the expression level of a gene, bases
aligned to any exon of the gene were counted and nor-
malized to the sum of gene exon lengths and to the total
number of aligned bases. Expression levels were scaled to
the number of single read bases aligned to 1 kbp of an exon
or gene, respectively, per 109 of total aligned bases.
Gene signature for CEBPA double mutants
Gene expression data were also employed to inspect pre-
viously published signatures that distinguish between
CEBPA double mutant carriers from CEBPA single mutant
and wild-type carriers [13, 14]. For this purpose, normalized
count data, either per gene or per exon, was filtered on
minimal expression with the requirement that at least 75%
of the samples should have a minimal expression of 1.
Remaining expression values were voom-transformed using
limma [15] for R and Z-scaled. Normalized expression
levels of genes or exons indicative of CEBPA double
mutation status were then plotted in a heatmap using the
ggplots2 R package (https://ggplot2.tidyverse.org).
Small variants
BAM files were processed using samtools mpileup (version
1.3.1) and VarScan (version 2.4.2) for variant calling. We
disabled the VarScan strand filter (--strand-filter 0), set the
minimum base frequency for variant calling to 10% of
the total depth at any given position (--min-var-freq 0.1), and
relaxed the p-value threshold to 0.05 (--p value 0.05). The
resulting VCF files were then filtered with the BEDtools suite
(version 2.21.0) for variants in 13 genes. The genes were
selected based on a mutation frequency of >5% in cosmic
AML samples and relevance for classification and prog-
nostication: NPM1 (Ensembl ID: ENSG00000181163), FLT3
(ENSG00000122025), DNMT3A (ENSG00000119772),
ASXL1 (ENSG00000171456), RUNX1 (ENSG00000159216),
CEBPA (ENSG00000245848), KIT (ENSG00000157404),
IDH1 (ENSG00000138413), IDH2 (ENSG00000182054),
TET2 (ENSG00000168769), NRAS (ENSG00000213281),
TP53 (ENSG00000141510), and WT1 (ENSG00000184937).
Since each of the 13 selected genes is mutated in >5% of
AML, a panel of 100 samples was selected in order to detect
genetic aberrations in each of the respective genes in at least
two different samples. Gene positions are defined according to
Ensembl ID throughout this manuscript. Filtered VCF files
were annotated using Variant Effect Predictor (VEP version
77) and included annotation of allele frequencies from the
1000 Genomes Project [16] and the Genome of The Nether-
lands (GoNL) [17]. Variants were filtered based on an allele
frequency of <5% in any of the subpopulations of the 1000
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Genomes Project [16] and the GoNL [17] and annotated for
allele frequencies and predicted effects. Based on somatic
mutations in AML as reported in COSMIC, mutation hotspot
regions were defined for NPM1, FLT3, DNMT3A, ASXL1,
KIT, IDH1, IDH2, and NRAS. Variants are displayed using a
custom R script that highlights its VEP-predicted impact on
the transcript. Initial screening revealed calling of an identical
TET2 ENST00000380013.6:c.5844dup in every sample that
could not be validated by RT-PCR and Sanger sequencing.
Therefore, this specific variant was excluded from the analysis
as sequencing artefact.
Detection of tandem duplications in FLT3 and
KMT2A
To detect internal tandem duplications in FLT3 (FLT3-ITD)
and partial tandem duplications in KMT2A (KMT2A-PTD),
FASTQ reads were aligned to the FLT3 primary gene
transcript (ENST00000241453) or KMT2A primary gene
transcript (ENST00000534358) using BWA MEM (version
0.7.13), setting the penalty of 5′ and 3′ clipping to 2 and 2
(-L 2,2), respectively. Samtools (version 1.3.1) was used to
discard unaligned reads. Alignment files were then com-
pressed, sorted, and indexed using the Picard suite (version
1.141). Soft-clipped (SC) fragments of reads partially
aligning to FLT3 exon 14–15 (1787–2024 in
ENST00000241453 and 1705–1942 in coding sequence) or
KMT2A exon 2–13 (456–4719 in ENST00000534358 and
433–4696 in coding sequence) were extracted by Fidus. SC
shorter than six bases (the ceiling of log4(region size)) were
discarded. Each SC is classified by its location at the start
(sSC) or end of the aligned region (eSC). Per SC class, local
alignment back to a portion of the target region was per-
formed to find its anchor position, defined as the unique
terminal position of the local alignment. Alignments with a
score of <50% of the possible maximum were discarded.
For a given soft clip sequence, partial ITD or PTD candi-
dates are defined as the region enclosed by its position and
its anchor position. Final ITD or PTD candidates are defined
as pairs of partial ITD or PTD candidates consisting of a
sSC and eSC that reciprocate each other within a maximum
fuzziness value, i.e., when the anchor region of a sSC
contains the soft clip position of an eSC or vice versa.
Calling of definite ITD or PTD candidates identified as the
region between reciprocal pairs of SC events was performed
by the newly developed Reciprocal Soft Clip Utilization
(ReSCU) algorithm.
The integrated HAMLET pipeline
All bioinformatic RNAseq analyses were integrated into the
HAMLET pipeline with a pdf file as primary output that
displays the analyzed, filtered, and annotated results of
fusion genes, small variants, FLT3-ITD, KMT2A-PTD, and
EVI1 expression in an easily interpretable graphic format.
Annotations include small variants with protein con-
sequences as determined by ENSEMBL Variant Effect
Predictor, i.e., coding single nucleotide variants (SNV) and
small indels. In addition, for all selected variants with
protein consequences, a short summary is provided with
information on variant type, protein consequence, read
depth, location in hotspots, annotation in COSMIC, anno-
tation as SNP with minor allele frequencies in different
human subpopulations, and effect on protein function as
predicted by PolyPhen and Sift scores.
Validation of HAMLET output
HAMLET results were interpreted by investigators in a
blinded fashion, i.e., without prior knowledge of routine
interphase cytogenetics, FISH analysis, and molecular
diagnostics of NPM1 and FLT3.
Fusion transcripts were correlated to routine metaphase
cytogenetics and FISH assays performed by the accredited
diagnostic LUMC Laboratory of Clinical Genetics. In
addition, fusion transcripts were extensively validated by
PCR with primers flanking the breakpoints.
Sequence variants were validated by PCR with custom
primers on cDNA generated from the same RNA source as
for RNAseq followed by Sanger sequencing or targeted
NGS. PCR amplification was performed using the PWO
SuperYield DNA Polymerase kit (Roche, Mannheim, Ger-
many) or Phusion Flash PCR kit (Thermo Fisher Scientific).
PCR products were purified using Wizard SV Gel and PCR
Clean-Up System kit (Promega Corporation). For targeted
NGS on cDNA, libraries were prepared from PCR products
by ligating barcoded TruSeq adapters (Illumina) using the
KAPA Library Preparation kit (KAPA Biosystems) [18].
After pooling the libraries, sequencing was performed on
the MiSeq sequencer (Illumina) using v3 sequencing
reagents according to the manufacturer’s protocol.
HAMLET results for small variants were also validated
by targeted NGS on genomic DNA isolated from 56 AML
cases. These AML were selected for genetic features asso-
ciated with an increased likelihood for mutations in TP53,
RUNX1, and TET2 according to Papaemmanuil et al. [9].
AML with complex karyotypes or −5/5q, −7/7q, −17/17p,
−12/12p, or +8/8q abnormalities were selected for an
increased likelihood for TP53 mutations. AML with
KMT2A-PTD, ASXL1, DNMT3A, NRAS, TET2, or FLT3-
ITD mutations were selected for an increased likelihood for
RUNX1 mutations, and AML with mutations in NPM1,
DNMT3A, NRAS, CEBPA, ASXL1, or RUNX1 for an
increased likelihood for TET2 mutations. Using bar-coded
primers for 222 amplicons, protein coding regions of RUNX1
(8 exons), TP53 (11 exons), TET2 (11 exons), KIT1 (21
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exons), and IDH1 (8 exons) were amplified as well as a large
part of the DNMT3A gene (exons 13–23). PCR was per-
formed on genomic DNA (14 ng) using primer pools
(Thermo Fisher Scientific, Waltham, MA), the Ion Ampli-
SeqTM Library Kit 2.0 (Thermo Fisher Scientific) and a
Bio-Rad C1000 Thermal Cycler (Bio-Rad Laboratories,
Hercules, CA). Barcoded samples were and pooled and
sequenced with a median depth of 1650 reads per amplicon
on the Ion GeneStudio S5 System (Thermo Fisher Scien-
tific). Sequencing data were aligned with the GRCh37 gen-
ome using TMAP 5.0.7 software and variants were called by
the Torrent Variant Caller (Thermo Fisher Scientific).
Detected variants after alignment to GRCh37 were converted
to corresponding positions in GRCh38 to the enable vali-
dation of variants called by HAMLET. Variants with allele
frequencies <10% were excluded from the analysis.
Expression of EVI1 was validated by quantitative RT-
PCR performed in the accredited diagnostic laboratory of
Erasmus Medical Center [11]. EVI1 expression relative to
the PBGD housekeeping gene was calculated using the
delta-delta CT method. Levels >0.1 relative to the EVI1-
overexpressing cell line SKOV3 were defined as positive.
Data deposition
Raw data files are available under controlled access in the
European Genome-phenome Archive under accession
numbers EGAC00001000956 (DAC), EGAS00001003096
(study), and EGAD00001004187 (dataset).
Results
Accredited mRNAseq on 100 AML samples (96 diagnostic
pre-treatment samples, three longitudinal samples of relap-
ses, one longitudinal sample of a presumed therapy-related
AML; Tables 1 and SI) yielded 48–85 million read pairs
(97–170 million reads) per case with a median insert size
(distance between the 5′ termini of the paired reads) of
149–177 bases (Table SII). The average read length after
quality control was 123–124 bases.
Detection of fusion genes
HAMLET accurately detected all recurrent fusion genes
that were predicted by metaphase cytogenetics in 24 cases
(Fig. 2a, Tables SIII and SIV). In three additional cases with
translocations involving 11q23 other than t(9;11)(p21;q23),
HAMLET correctly identified the KMT2A fusion partners
MLLT1, MLLT4, and MLLT6 in accordance with respective
balanced translocations (Figs. 2b and S1). In addition,
HAMLET correctly identified fusion transcripts in eight
cases that were not predicted by metaphase karyotyping but
carry known prognostic relevance for AML (Fig. 2b,
Table SV). In one case (2-038), the FUS-ERG fusion event
was detected whose corresponding t(16;21)(p11;q22) was
only identified retrospectively within its complex
Table 1 Characteristics of AML samples analyzed by RNAseq.
Characteristics No. of AML
Number of patients 100
Age (median, years) 53 (22–77)
Gender
Male 55
Female 45
WHO diagnosis
AML with t(9;11); KMT2A-MLLT3a 4
AML with inv(16); CBFB-MYH11a 10
AML with t(8;21); RUNX1-RUNX1T1a 3
Acute promyelocytic leukemia with t(15;17);
PML-RARAa
2
AML with inv(3); GATA2, MECOMa 2
AML with t(6;9); DEK-NUP214 1
AML with mutated NPM1b 35
Acute monoblastic/monocytic leukemia 11
AML with myelodysplasia-related changes 13
AML NOS with maturati 9
AML NOS with minimal differentiation 1
AML NOS without maturation 12
Acute myelomonocytic leukemia 3
Therapy-related AML 2
AML
Primary 95
Relapse 5
Source
Bone marrow (BM) 78
Peripheral blood (PB) 22
Blast percentage (median) 75 (13–99)
Karyotypec
Normal karyotype 45
Complex karyotype 8
Abnormal karyotype 37
No metaphases 2
FLT3-ITDb 34
aRecurrent fusion transcripts CBFB-MYH11 inv(16)(p13q22),
KMT2A-MLLT3 t(9;11)(p21;q23), RUNX1-RUNX1T1 t(8;21)(q22;
q22), and PML-RARA t(15;17)(q24;q21) as well as chromosomal
translocation GATA2, MECOM inv(3)(q21q26) were detected by
fluorescence in situ hybridization (FISH) on 200 interphases per
probe set.
bGenotyping for NPM1 and FLT3-ITD mutations was performed by
routine diagnostic PCR on genomic DNA followed by electrophoretic
fragment size analysis.
cKaryotype was determined by cytogenetics on at least 20 metaphases
per case.
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karyotype. The karyotype of one AML (2-020) that carried
the ETV6-LYN fusion gene had an add(8)(q24) and del(12)
(p13) but lacked the characteristic ins(12;8)(p13;q11q21)
[19, 20]. Three AML (2-003, 2-031, 2-032) expressed
NUP98-NSD1 fusion transcripts. Due to telomeric positions
of both participating genes, the NUP98-NSD1 originates
from a cryptic t(5;11)(q35;p15.5) and is therefore currently
neglected by AML classifications despite its association
with poor prognosis [21–23]. PIM3-SCO2 is an important
example of an intrachromosomal fusion event that was
found in three cases (2-053, 3-021, 3-024). It has previously
been found in pediatric AML and can originate from a 0.6
Mb chromosome 22 inversion in chronic neutrophilic leu-
kemia [24].
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Fig. 2 Detection of fusion genes by HAMLET. a Detection of fusion
genes with prognostic relevance for AML included in the WHO 2016
classification. Examples shown: CBFB-MYH11 of the inv(16)(p13q22)
(case 2-004), RUNX1-RUNX1T1 of the t(8;21)(q22;q22) (case 3-007),
and KMT2A-MLLT3 of the t(9;11)(p21;q23) (case 3-001). b Detection
of fusion genes with prognostic relevance for AML not included in the
WHO 2016 classification. Examples shown: KMT2A-MLLT6 of the t
(11;17)(q23;q21) (case 3-010), NUP98-NSD1 of the cryptic t(5;11)
(q35;p15.5) (case 2-031 with normal karyotype), and ETV6-LYN of a
cryptic ins(12;8)(p13;q11q21) in a case (2-020) with add(8)(q24) and
del(12)(p13). Gels adjacent to the circus plots depict validation by RT-
PCR with custom primers (Table SVI). An amplicon of 279 bp
demonstrated fusion of KMT2A exon 7 to MLLT6 intron 10 (case 3-
010). Amplicons of 209 and 350 bp demonstrated fusion of NUP98
exon 11 or 12 to NSD1 exon 7 (cases 2-003, 2-031, 2-032). An
amplicon of 181 bp demonstrated fusion of ETV6 exon 5 to LYN exon
8 (case 2-020). All fusion transcripts were validated by sequencing
(Tables SIII and SV).
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HAMLET provided detailed structural information on
fusion transcripts, including differential splicing (KMT2A-
MLLT3, RUNX1-RUNX1T1, PML-RARA, CBFB-MYH11,
and NUP98-NSD1) and reciprocal transcripts from balanced
translocation, e.g., RARA-PML, ERG-FUS, NUP214-DEK,
and NSD1-NUP98 (Table SIII). In total, HAMLET detected
54 different fusions transcripts that were not predicted by
metaphase karyotyping (Tables SV and SVI, Fig. S2).
Overall, 28 AML carried two or more fusions with a
maximum of nine different fusions in an AML with com-
plex karyotype.
Detection of small variants
The VARSCAN component of HAMLET identified
246 small variants in the selected 13 AML genes with 100%
specificity (Tables 2, SVII, and SVIII). The sensitivity of
HAMLET was assessed for FLT3-ITD and hotspot regions
of NPM1 and DNMT3A in all 100 cases and for the
remaining gene regions a total of 418 targeted resequencing
reactions on samples that were called as wild type by
HAMLET (Table 2). In accordance with the well-known
limitation of regular variant callers to detect longer inser-
tions [9], VARSCAN identified only seven rather short
FLT3-ITD of the 34 FLT3-ITD-carrying AML. Further-
more, HAMLET failed to call a 23 bp ASXL1 deletion
(c.1900_1922del; case 3-030) and a 30 bp C-terminal
CEBPA insertion (c.936_937ins30; case 3-003). In both
cases, HAMLET correctly identified a canonical C-terminal
insertion in ASXL1 (3-030) and a N-terminal frameshift
mutation in CEBPA (3-003). The overall type (coding SNVs
and in-frame or frameshift indels) and distribution of the
small variants as detected by HAMLET corresponded well
with their distribution as reported in COSMIC (Fig. S3).
Variants called by HAMLET that are listed in COS-
MIC and located within defined genetic hotspots
(Table SIX) are readily interpretable as pathogenic class A
variants (n= 114; 46.3%) (Table SVII). Sixty variants
(24.4%) were reported in COSMIC but not located in
hotspots. Most of these class B variants were detected in
genes where mutations are known to occur throughout the
entire coding sequence (CEBPA, TET2, RUNX1, WT1,
and TP53). The remaining variants were unreported (class
C variants: n= 52; 21.1%) or not listed in COSMIC but
described as SNP (class D variants, n= 20; 8.1%). Class
D variants probably represent true genetic polymorphisms
with low allele frequency. Class C variants can be inter-
preted based on their predicted pathogenic effects.
According with these principles for interpretation, more
than 90% of class A variants, app. 50% of class B and C
variants, and <1% of class D variants have been reported
as recurrent mutations in myeloid malignancies by Jaiswal
et al. [25] (Table SVII).
In the TCGA AML cohort [3], small variants that are
present in genomic DNA have been shown to be absent in
the corresponding RNA sequence analysis. In particular
nonsense variants and frameshift variants with a premature
stop codon may be poorly expressed as a result of nonsense-
mediated RNA decay [26, 27]. We therefore validated
HAMLET results for small variants in RUNX1, TET2,
TP53, DNMT3A, KIT1, and IDH1 by targeted NGS on
genomic DNA isolated from 56 AML. These cases were
selected for genetic features associated with an increased
likelihood for mutations in TP53, RUNX1, and TET2
according to Papaemmanuil et al. [9]. In these 56 AML
cases, HAMLET detected 67 variants including 18 non-
sense and frameshift variants that are potential targets for
nonsense-mediated RNA decay. Of these 67 variants, one
TET2 variant (c.4317dup) in three AML cases was missed
by targeted NGS (Table SX). This A insertion occurs in a
stretch of 6 other A nucleotides, which is apparently diffi-
cult to sequence on the Ion GeneStudio S5 System. Reads
for this variant were present in the raw data with allele
frequencies of 2–3%. There were also two variants detected
by targeted NGS that were missed by HAMLET. These
variants included a RUNX1 missense variant which has
been detected by targeted NGS with a low allele frequency
of 10% and a polymorphism in IDH1. In conclusion, our
data showed that HAMLET accurately called variants in
TET2, TP53, RUNX1, KIT, IDH1, and DNMT3A including
all variants encoded by transcripts that are potential targets
for nonsense-mediated decay. We also determined the
sequencing depth that is required to detect small variants by
HAMLET-RNAseq and ran the pipeline on 20, 30, 40, and
47.5 million read pairs for each of the 100 AML. Of the 246
variants called by HAMLET, 53 variants were nonsense
mutations or frameshift mutations with a premature stop.
The sensitivity of HAMLET to detect these variants
decreased from 100, 96, 85 to 70%, while the decrease for
the remaining variants was from 100, 98, 96 to 81%. These
data show that a high sequencing depth of ~50 million read
pairs is essential to ensure detection of all variant types
including potential targets for nonsense-mediated RNA
decay (Table SXI and Fig. S4).
Bi-allelic CEBPA mutations confer a favorable prognosis
to patients with AML with a normal karyotype [1, 8] and
typically combine an N-terminal frameshift mutation within
the first 357 bp of the coding sequence on one allele with a
C-terminal in-frame insertion or deletion between c.834-
1074 that disrupts the DNA-binding basic zipper (bZIP)
domain on the other allele [28]. The distance between these
events frequently precludes formal proof of their location
on opposite chromosomes by commonly achievable
read lengths on the Illumina platform. However, bi-allelic
CEBPA mutations are associated with a specific gene
expression profile [13, 14]. mRNAseq-based gene
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expression profiling showed the characteristic bi-allelic
CEBPA mutation-associated signature for all four AML
samples carrying two CEBPA mutations (2-009, 2-039, 2-
045, and 3-003), including case 3-003 whose C-terminal
mutation was missed by HAMLET (Fig. 3). Of eleven AML
with single CEBPA variants, one case (2-025) with the
characteristic N-terminal frameshift mutation clustered with
the double CEBPA mutants. Combined analyses of variant
calling and gene expression profiling can therefore resolve
uncertainties of variant calling alone. Since the gene sig-
nature for CEBPA double mutants is descriptive and not
quantitative, it has not been implemented for clinical use in
HAMLET.
Detection of tandem duplications in FLT3 and
KMT2A
Reliable detection of the common tandem duplications in
exon 14–15 of FLT3 is of special importance in AML
diagnostics since presence of the FLT3-ITD is an indication
for therapy with a tyrosine kinase inhibitor [29]. In addition
to the categorical detection of a FLT3-ITD, its position,
size, and mutant-to-wild-type allelic ratio have important
prognostic impact in AML [30–32]. To improve the insuf-
ficient detection of FLT3-ITD by VARSCAN, we devel-
oped ReSCU as novel algorithm based on calling of
partially aligning, SC reads that occur at reciprocal gene
positions (Fig. S5).
ReSCU identified 36 cases with a FLT3-ITD, including
all seven cases with a small ITD as detected by VARSCAN
and all 34 cases identified by accredited diagnostics
(Fig. 4a; Tables SXII and SXIII). Targeted resequencing by
NGS additionally confirmed presence and length of the
FLT3-ITD at positions identified by the soft clipping
approach in all but two of these cases (Table SXIV). In the
two discrepant cases that were called by ReSCU but not by
standard diagnostics, the SC reads represented <1% of total
coverage at their respective positions. Careful review of the
raw data of the results of the accredited test revealed a weak
FLT3-ITD signal below the detection threshold in both
cases, suggesting higher sensitivity for HAMLET (Fig. S6).
The allelic ratio of mutant-to-wild-type FLT3 fragments
Table 2 Validation of sequence variants in 13 selected AML genes as detected by HAMLET.
Gene Region HAMLET component HAMLET: mut wt mut wt Sensitivity (%) Specificity (%)
Validation: mut mut wt wt
NPM1 Hotspot VARSCAN 35 0 0 65 100 100
DNMT3A Hotspot VARSCAN 15 0 0 85 100 100
Outside hotspot VARSCAN 17 0 0 17 100 100
FLT3 Hotspot ex20 VARSCAN 8 0 0 17 100 100
Outside hotspot VARSCAN 12 0 0 13 100 100
ASXL1 Hotspot VARSCAN 13 1 0 18 92.9 100
CEBPA Entire gene VARSCAN 18 1 0 18 94.7 100
IDH1 Hotspot VARSCAN 7 0 0 14 100 100
Outside hotspot VARSCAN 7 0 0 16 100 100
IDH2 Hotspot VARSCAN 12 0 0 12 100 100
Outside hotspot VARSCAN 4 0 0 22 100 100
KIT Hotspot VARSCAN 7 0 0 13 100 100
Outside hotspot VARSCAN 3 0 0 8 100 100
NRAS Hotspot VARSCAN 14 0 0 15 100 100
RUNX1 Entire gene VARSCAN 21 0 0 28 100 100
TET2 Entire gene VARSCAN 34 0 0 34 100 100
TP53 Entire gene VARSCAN 3 0 0 12 100 100
WT1 Entire gene VARSCAN 9 0 0 11 100 100
TOTAL VARSCAN 239 2 0 418 99.2 100
FLT3 Hotspot ex14-15 ReSCU 34 0 2 64 100 97.0
KMT2A Hotspot ex2-13 ReSCU 8 0 0 4 100 100
TOTAL ReSCU 42 0 2 68 100 97.1
TOTAL VARSCAN and ReSCU 281 2 2 486 99.3 99.6
Validation of NPM1 mutations and FLT3-ITD was performed by PCR on genomic DNA and electrophoretic fragment size analysis. Validation of
other variants was performed by RT-PCR on cDNA followed by Sanger sequencing or NGS using MiSeq. Gene hotspots are defined in Table SVI.
mut variant detected, wt wild type.
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correlated well with percentages of SC reads as called by
ReSCU (Fig. 4b).
KMT2A-PTD in exons 2–13, which are essential to
classify AML to the chromatin-spliceosome group [9], lead
to elongated proteins that adversely affect clinical outcome
of AML [33]. ReSCU identified KMT2A-PTD of exon 2–8
and 2–10 in four and two cases, respectively, and duplica-
tions of exon 2, 2–3, and 3–6 in single cases (Fig. 4c;
Table SXV). All nine KMT2A-PTD were validated by RT-
PCR and sequencing (Fig. S7 and Table SXVI).
Detection of gene overexpression
Overexpression of structurally normal genes can influence
outcome of AML patients as reported for BAALC, ERG,
MN1, DNMT3B, SPARC, and EVI1 [8]. The reliability of
mRNAseq to measure overexpression was assessed for the
EVI1 transcript that heralds a very poor prognosis in AML
(Fig. 5a) [10–12]. Overexpression of EVI1 can be caused by
inv(3)(q21q26) or t(3;3)(q21;q26), but alternative molecular
mechanisms exist [12, 34]. EVI1 exon 1 expression as
detected by mRNAseq correlated well to quantitative RT-
PCR measurements (Fig. 5b). High EVI1 expression was
seen in both cases (1-005, 3-029) carrying inv(3)(q21q26)
and one case (1-008) with t(3;8)(q26;q24) (Table SXVII).
Of four additional cases with high EVI1 expression, one had
a der(3)t(1;3)(q3?1;q2?5) without identifiable involvement
of the MECOM1 locus (case 3-022). All three cases over-
expressing EVI1 without 3q26 abnormalities carried
KMT2A fusion transcripts (cases 1-001 and 3-008: KMT2A-
MLLT3; case 2-047: KMT2A-MLLT4; see Table SIII). This
combination of genetic aberrations indicates an extremely
poor prognosis in AML [35–37].
Clonal evolution
HAMLET revealed clonal evolution with acquisition and
loss of genetic aberrations in all four pairs of samples taken
at diagnosis and subsequent relapse (Table SXVIII). Per-
sistence of an IDH2 mutation as the presumed founding
event established a common origin of a de novo AML and
subsequent presumed therapy-related AML despite mark-
edly divergent genotypes (cases 3-021, 3-038). Therefore,
the diagnosis of an independent, therapy-related AML was
corrected to relapse of the original AML, although both
samples would be classified as different AML subtypes.
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Fig. 3 Detection of double CEBPA mutants. Expression was ana-
lyzed by RNAseq for 16 genes included in the 19-probe signature
associated with bi-allelic CEBPA mutants [14]. Up- and down-
regulated expression levels are shown in green and red, respectively.
All 100 AML cases are indicated on the Y-axis. All three double
CEBPA mutants shared the same gene signature (2-009, 2-039, and 2-
045). Two single CEBPA mutant cases (2-025, 3-003) clustered with
the double mutants. Sanger sequencing revealed that one case (3-003)
had a 30 bp C-terminal insertion that was missed by HAMLET, while
the other case was a true single N-terminal mutant without C-terminal
mutation (2-025). Similar results were obtained for the proposed 55-
probe signature (data not shown) [13].
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Fig. 4 Detection of tandem repeats in FLT3 and KMT2A by the
ReSCU algorithm. Graphs depict the ratio of soft-clipped (SC) reads-
to-total coverage (left Y-axis; yellow peaks) and total read coverage
(right Y-axis; gray areas) for each position. Reciprocal events at
identical and close positions are indicated by solid and dotted lines,
while red and purple lines represent dominant and subdominant events,
respectively. a FLT3 exons 14–15 (1787–2024 in ENST00000241453
and 1705–1942 in coding sequence). AML cases are representative for
a reciprocal event with high SC reads-to-total coverage (2-029), a case
with dominant and subdominant reciprocal events (1-003), a reciprocal
event with low SC reads-to-total coverage (3-009), and a case without
ITD (1-001). b Comparison of FLT3-ITD results by HAMLET and
diagnostic PCR. Diagnostic PCR was performed on genomic DNA
using NED-5′-GTAAAACGACGCCCAGTCTGAAGCAATTTAG
GTATGAAAGC-3′ and VIC-5′-GGAAACAGCTATGACCATGTA
CCTTTCAGCATTTTGACG-3′ as forward and reverse primers,
respectively. Left panel: SC reads-to-total coverage by HAMLET (X-
axis) versus allelic ratios by diagnostic PCR calculated from areas
under the curve for mutant and wild-type FLT3 fragments after
capillary electrophoresis (Y-axis). SC reads-to-total coverage is the
sum of dominant and subdominant ITD and average between start and
end of ITD. Right panel: ITD length as determined by HAMLET (X-
axis) versus diagnostic PCR (Y-axis). Two subdominant ITD in case 3-
027 (green dots) were detected by HAMLET with <0.5% SC reads-to-
total coverage but not by routine diagnostics. Three subdominant ITD
in cases 2-015, 2-032, and 2-046 (red dots) were detected by routine
diagnostics but not by HAMLET. All dominant clones were called by
both tests. c KMT2A exons 2–13 (456–4719 in ENST00000534358
and 433–4696 in coding sequence). AML cases are representative for
duplications of exon 2–8 (2-002), exon 2 and exon 2–3 (2-027), exon
3-6 (2-013), exon 2-10 (2-054), and a case without PTD (2-005).
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Classification and prognostication of AML
Based on HAMLET and metaphase karyotyping results, 99
cases could be reclassified according to WHO 2016 and
genomic classifications (Fig. 6) [8, 9]. For this genetic
classification and risk assessment, all variants were selected
that have been reported as recurrent mutations in hemato-
logical malignancies by Jaiswal et al. [25]. HAMLET
information facilitated risk reassessment in six cases, most
notably assignment to adverse risk through NUP98-NSD1
fusions in AML without class-defining lesions, or through
EVI1 overexpression without inv(3)(q21q26).
Discussion
This study demonstrates the feasibility and accuracy of
mRNAseq for the classification and prognostication of
AML. Our strategy is built on the novel diagnostic para-
digm to capture comprehensive genetic information on a
single platform and interrogation of the primary data with
respect to currently relevant information. Results of the
individual case analysis are reported automatically in a user
friendly, easily interpretable format. Both elements of this
strategy can improve independently with advances in sam-
ple processing and sequencing technology. Relevant new
insight into AML subtypes, prognostic factors, and
actionable targets can be readily incorporated into the
HAMLET algorithm. By linking mRNAseq output to public
databases, reliable data interpretation is possible without
concomitant germ-line DNA sequencing. Advances in
sequencing technology can be implemented to improve
diagnostic sensitivity with regard to minor AML subclones
without major redevelopment of the data analysis.
HAMLET accurately detects fusion genes with diag-
nostic relevance for AML, including KMT2A fusions not
originating from a t(9;11) but from various different partner
genes [38]. Accurate detection of the oncogenic fusion
genes ETV6-LYN [19, 20], NUP98-NSD1 [21–23], and
PIM3-SCO2 [24] facilitates their recognition as genetically
defined entities for AML classification. The remarkable
robustness in detecting fusion genes should render HAM-
LET especially valuable to recognize various fusions of
tyrosine kinase genes in Philadelphia chromosome-like
acute lymphoblastic leukemia [39].
Independent of the percentage of leukemic blasts in the
samples, HAMLET 1.0 identified small variants in 13 fre-
quently mutated AML genes with a chosen threshold of
10% variant reads with 99.2% sensitivity and 100% speci-
ficity. Nevertheless, it must be taken into account that very
low blast counts in AML samples will limit the sensitivity
of HAMLET to detect pathogenic variants. On the other
hand, we predict that the detection of minor subclonal
variants will be reliably possible with increasing sequencing
A
B
1 2 3 4
MDS1 EVI1
Fig. 5 Detection of EVI1
overexpression. a Schematic
representation of two mRNA
transcripts from the MECOM
locus on chromosome 3. One
transcript contains exon 1–2 of
MDS1 fused to exon 2–15 of
EVI1 (MDS1-EVI1 transcript),
whereas the other transcript
contains exon 1–15 of EVI1
(EVI1 transcript). b Comparison
of EVI1 expression by RNAseq
and quantitative RT-PCR. X-
axis: Expression of the first exon
of EVI1 normalized for
expression of the PBGD
housekeeping gene by
quantitative RT-PCR (log2
EVI1/PBGD). Y-axis: Sum of
base coverage of the first exon
of EVI1 per kb transcript and
one million mapped reads (log2
BPKM) by RNAseq.
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depth. As known for variant callers such as VARSCAN,
two relatively large indels of 23–30 bp were missed.
Detection of such indels may be improved by identification
of SC reads as already implemented in HAMLET for
duplications in FLT3 and KMT2A. Large duplications are
notoriously problematic for conventional algorithms
including Pindel, even when reads are aligned to large
custom libraries of observed duplications and after manual
correction [9]. However, integrated calling of SC reads
accurately predicted the presence, positions, and length of
tandem duplications of interest. Since the majority of
KMT2A-PTD involve multiple exons and introns, long
regions need to be screened to identify these mutations as
readily accomplished by ReSCU. The prognostically rele-
vant mutant-to-wild-type FLT3-ITD allelic ratio are dedu-
cible from mRNAseq data. This aspect, however, currently
warrants further calibration. However, determination of this
ratio at the transcriptional level as achieved by mRNAseq
may be preferable to DNA analysis [40]. Moreover, ITD
transcript length of at least 48 bp after splicing of intron
14–15 is associated with poor survival [30, 31, 41, 42].
The intrinsic quantification of gene expression by
mRNAseq readily permits measurement of EVI1 expres-
sion, whose overexpression heralds a very poor prognosis
even in the absence of structural aberrations involving 3q26.
Combined information on gene expression profiles and
sequence variants can also resolve difficulties in sequence
interpretation as demonstrated for CEBPA variants. The
characteristic expression profile of double CEBPA mutants
in a case with a single N-terminal CEPBA frameshift
mutation could potentially be due to silencing of the wild-
type CEBPA allele by hypermethylation and could possibly
indicate a similarly favorable prognosis [43, 44]. Gene
signatures also lend themselves for increasing the diagnostic
accuracy of identification of FLT3-ITD [45] and NUP98-
NSD1 fusions [21, 23].
AML sample 
2-
01
4
2-
00
6
1-
00
7
3-
00
2
3-
00
7
2-
04
3
2-
04
4
3-
02
5
2-
00
7
3-
01
4
2-
01
0
3-
03
9
1-
00
4
2-
05
3
2-
00
4
2-
00
5
3-
00
8
1-
00
1
3-
00
1
2-
05
2
3-
02
9
1-
00
5
2-
03
4
3-
03
2
3-
01
3
2 -
04
1
3-
01
9
2-
05
1
3 -
02
1
3-
02
3
3-
03
4
2-
02
8
2-
01
1
2-
04
8
2-
01
2
3 -
03
5
3-
00
9
3-
02
0
2 -
04
9
1-
00
2
2-
01
6
2-
01
8
2-
03
5
3-
02
7
3-
01
2
3-
01
1
2-
01
5
2-
03
3
2-
02
9
2-
00
1
2-
04
6
3 -
00
5
3-
04
1
1-
00
3
2-
03
0
3-
03
7
2-
02
3
2-
00
9
2-
03
9
3-
00
3
2 -
04
5
2-
00
8
3-
01
7
2-
01
3
3-
00
6
2-
03
7
1-
00
8
2-
03
6
2-
04
0
3-
03
1
2-
05
0
3-
03
8
2-
01
9
3-
01
5
1-
00
6
3-
02
2
2 -
03
8
3-
01
6
3-
02
8
2 -
02
0
2-
02
1
3-
03
0
2-
02
7
3-
02
4
3-
04
2
2-
00
2
2-
05
4
2-
04
7
3-
01
0
2 -
02
2
3-
04
0
2-
00
3
2-
03
1
2-
03
2
3-
01
8
2-
02
4
2-
02
5
3-
00
4
3-
02
6
3-
03
3
AML Subtypes 
according to 
classification
WHO 2016
PM
L -
R
A
R
A
R
U
N
X-
R
U
N
X1
T1
CBFB-MYH11
KMT2A-
MLLT3
D
EK
-N
U
P
in
v3 NPM1 mut AML
C
EB
PA
bi
al
le
lic
m
ut
A
M
L
RUNX1
mut
AML
AML with 
MDS tA
M
L
AML NOS
Genomic t(11;x) Splicesome TP53/Aneuploidy
t(11;x)
R
17
2
AML w/ drivers
WHO 
classification-
defining 
translocations
PML-RARA
RUNX1-RUNX1T1 
CBFB-MYH11 fusion gene /
KMT2A-MLLT3 translocation
DEK-NUP214 present
GATA2, MECOM 
WHO 
classification-
defining 
mutations
NPM1 monoallelic
CEBPA biallelic
RUNX1 
Class-defining 
lesions of 
Genomic 
classification 
ASXL1 
KMT2A-PTD 
TP53 
Aneuploidy/Complex 
KMT2A fusions
Actionable 
Targets
IDH2 R172 
FLT3-ITD high allelic ratio
FLT3-TKD 
IDH1 R132 
IDH2 R140 
KIT D816 
NRAS G12 & G13 
NRAS Q61 
Other 
mutations
DNMT3A R882 
DNMT3A non-R882 
WT1 
TET2 
Fusions genes 
neglected by 
WHO 
classification
ERG-FUS 
NUP98-NSD1 
PIM3-SCO2 
ETV6-LYN 
Gene 
expression 
profiling
CEBPA gene signature 
MECOM/EVI1 high adverse risk
Risk
ELN intermediate risk
ELN-HAMLET favorable risk
Fig. 6 Classification, risk assessment, and actionable targets as
derived from HAMLET output and metaphase cytogenetics. AML
cases are primarily ordered according to the WHO 2016 classification
and secondarily according to the proposed genetic AML classification
[9]. Relevant variants with respect to the genetic classification and
potentially actionable targets are indicated per case. Red font indicates
parameters provided by HAMLET that cannot be reliably addressed by
metaphase cytogenetics and targeted NGS sequencing. Prognosis
according to the ELN risk [1] is indicated at the bottom. In addition,
cases whose ELN risk was altered by HAMLET information are
indicated. Red boxes mark the HAMLET parameter that modifies ELN
risk. Except for aneuploidies and complex karyotypes, HAMLET
provides all information required for risk assessment. Arrows point
from a diagnostic sample to the relapse in the same patient. AML with
MDS AML with myelodysplasia-associated changes, tAML therapy-
related AML, Mut mutated, AML NOS AML not otherwise specified,
ELN European leukemia net.
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We classified our 100 AML according to Papaemmanuil
et al. [9] and selected all genetic aberrations called by
HAMLET and filtered for predicted importance according
to large AML sequencing datasets [25]. Of the 100 AML,
88 cases were classified in single entities, three cases in two
subgroups and nine cases had no class-defining lesions. Of
the nine cases without class-defining lesions, eight cases
had detectable driver mutations and one case had no
detectable driver mutation. These numbers perfectly match
reported percentages [9], indicating that HAMLET accu-
rately called all genetic information for current classification
of AML. Of the 16 additional genes that we are currently
implementing in HAMLET (version 2.0), seven genes are
relevant for classification and belong to the chromatin-
spliceosome group. Mutations in these genes, however, are
less frequent and did not affect classification of the 100
AML (data not shown).
Our current experience with RNAseq-HAMLET indi-
cates its potential to replace all genetic tests for classifica-
tion and risk assessment of AML except for metaphase
cytogenetics, which is still required to detect complex kar-
yotypes and aneuploidies. Since RNAseq has successfully
been used to detect large chromosomal aberrations in acute
lymphoblastic leukemia [46], the aim is to implement this in
the next HAMLET version. Although multiplexed PCR and
targeted NGS on large gene panels is currently widely
implemented in routine diagnostics, long duplications and
GC-rich genes remain difficult to sequence by targeted NGS
and are therefore often missed (KMT2A-PTD) or analyzed
separately (FLT3-ITD and CEBPA). As demonstrated by
downsampling the number of RNA reads (Tables SIV, SXI,
and SXIII), a sequencing depth of ~50 million read pairs is
essential to accurately detect all structurally diverse genetic
aberrations in AML. A high sequencing depth is particularly
needed to detect nonsense and frameshift variants with a
premature stop that may be poorly expressed due to
nonsense-mediated RNA decay [3, 26, 27]. This is also the
case for genetic aberrations detected by reads that partially
align to the GRCh38 genome such as junction reads and
spanning fragments for detection of fusion transcripts, as
well as SC reads for detection of long tandem duplications
in FLT3 and KMT2A. While measurement of FLT3-ITD
allelic ratios should be performed on DNA according to the
ELN recommendations [1], a recent study in pediatric AML
suggests measuring FLT3-ITD preferentially on RNA, since
ITD expression is more strongly associated with poor
overall survival than its presence per se [40]. However,
RNA-based assays should be sufficiently sensitive to detect
FLT3-ITDs in AML subclones in order to start treatment
with FLT3 inhibitors [29].
HAMLET results at a sequencing depth of 50 million
read pairs can be obtained at a competitive price compared
with the conventional diagnostic workflow within 5 days
from sample receipt to finished report. The pipeline requires
4 h for sample receipt and isolation of mononuclear cells,
1 h for isolation of total RNA, 24 h for mRNA isolation, and
cDNA library preparation, 44 h for RNA sequencing, 24 h
for RNAseq analysis and 15 min for data interpretation
(excluded time for sample shipment, data transfer and other
logistics that are dependent on geographic location, com-
putational networks and negotiations).
In conclusion, HAMLET appears to be a reliable
approach to obtain comprehensive genetic information with
prognostic and therapeutic relevance for AML in a single
assay. RNAseq-based diagnostics also have potential for
improved risk assessment and prediction of sensitivity to
targeted agents on an individual basis [4, 47]. Based on
results of the present study, we are currently implementing
HAMLET as routine diagnostic procedure at Leiden Uni-
versity Medical Center to improve risk-classification and
personalized treatment of AML.
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